ABM Therapeutics

Company Drug

ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma

Fineline Cube Aug 3, 2023

Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...

Company Drug

ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors

Fineline Cube May 5, 2023

Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...

Company Drug

InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline